One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Alkermes Plc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Alkermes Plc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Alkermes Plc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Alkermes Plc (ALKS)

Before we jump into Alkermes Plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Want to learn more about Alkermes Plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alkermes Plc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Alkermes Plc’s Stock Price as of Market Close

As of August 30, 2023, 4:00 PM CST, Alkermes Plc’s stock price was $29.11.

Alkermes Plc is up 7.1% from its previous closing price of $27.18.

During the last market session, Alkermes Plc’s stock traded between $27.01 and $27.41. Currently, there are 166.28 million shares of Alkermes Plc stock available for purchase.

Alkermes Plc’s price-earnings (P/E) ratio is currently at 48.0, which is high compared to the Biotechnology & Medical Research industry median of 21.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Alkermes Plc Stock Price History

Alkermes Plc’s (ALKS) price is currently down 0.58% so far this month.

During the month of August, Alkermes Plc’s stock price has reached a high of $29.99 and a low of $25.68.

Over the last year, Alkermes Plc has hit prices as high as $33.71 and as low as $21.75. Year to date, Alkermes Plc’s stock is up 25.15%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alkermes Plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 29, 2023, there was 1 analyst who downgraded Alkermes Plc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alkermes Plc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Alkermes Plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alkermes Plc (ALKS) by visiting AAII Stock Evaluator.

Relative Price Strength of Alkermes Plc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of August 29, 2023, Alkermes Plc has a weighted four-quarter relative price strength of -1.97%, which translates to a Momentum Score of 57 and is considered to be Average.

Want to learn more about how Alkermes Plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alkermes Plc Stock Price: Bottom Line

As of August 30, 2023, Alkermes Plc’s stock price is $29.11, which is up 7.1% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Alkermes Plc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.